{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1882","pValueComment":"Two-sided p-value from log-rank test stratified by EGFR mutation group and race.","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.618","ciPctValue":"95","ciUpperLimit":"1.104","estimateComment":"Afatinib 40 mg vs. Pemetrexed/Cisplatin Chemotherapy, if HR\\<1 then favours Afatinib 40 mg.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0427","paramType":"Hazard Ratio (HR)","paramValue":"0.826","statisticalComment":"Cox PH regression stratified by EGFR mutation group and race.","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.79","upperLimit":"5.59","value":"4.17"},{"groupId":"OG001","lowerLimit":"2.17","upperLimit":"3.98","value":"3.09"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"HRQOL was measured by EORTC QLQ-C30 and its lung cancer specific module QLQ-LC13. Analysis for pain is based on composite of QLQ-C30 questions 9 and 19. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"OG001","title":"Pemetrexed/Cisplatin Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"RS.","reportingStatus":"POSTED","timeFrame":"Throughout the trial until progression (every 3 weeks).","title":"HRQOL: Time to Deterioration in Pain","type":"SECONDARY","unitOfMeasure":"Months."}